Your browser doesn't support javascript.
loading
Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
Gunter, Simon J; Holcomb, Zachary E; Lam, Barbara D; Porter, Martina L; Kimball, Alexa B.
Affiliation
  • Gunter SJ; Harvard Medical School, Boston, Massachusetts.
  • Holcomb ZE; Section of Dermatology, Department of Medicine, Carilion Clinic, Roanoke, Virginia.
  • Lam BD; Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Porter ML; Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Kimball AB; Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
JAMA Dermatol ; 160(6): 678-681, 2024 Jun 01.
Article in En | MEDLINE | ID: mdl-38717768
This post hoc analysis of PIONEER I and II randomized clinical trials assesses whether receiving adalimumab is associated with decreased hematologic abnormalities and increased clinical improvement in patients with hidradenitis suppurativa.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hidradenitis Suppurativa / Adalimumab Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Dermatol Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hidradenitis Suppurativa / Adalimumab Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Dermatol Year: 2024 Document type: Article